key: cord-0025977-jsk7em47
authors: Kim, Ji Yeun; Lim, So Yun; Park, Soonju; Kwon, Ji-Soo; Bae, Seongman; Park, Ji Young; Cha, Hye Hee; Seo, Mi Hyun; Lee, Hyun Jung; Lee, Nakyung; Kim, Kideok; Shum, David; Jee, Youngmee; Kim, Sung-Han
title: Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period
date: 2021-11-25
journal: J Infect Dis
DOI: 10.1093/infdis/jiab579
sha: 350dfacc08f487b9228f0d97f0e8fb236759e2b2
doc_id: 25977
cord_uid: jsk7em47

BACKGROUND: There are limited data directly comparing immune responses to vaccines and to natural infections with COVID-19. This study assessed the immunogenicity of the BNT162b2 and ChAdOx1 nCoV-19 vaccines over a 3-month period and compared the immune responses with those to natural infections. METHOD: We enrolled healthcare workers (HCWs) who received BNT162b2 or ChAdOx1 nCoV-19 vaccines and COVID-19-confirmed patients, and then S1-IgG and neutralizing antibodies and T cell responses were measured. RESULTS: A total of 121 vaccinees and 26 patients with confirmed COVID-19 were analyzed. After the 2 (nd) dose, the BNT162b2 vaccine yielded S1-IgG antibody responses similar to natural infections (2241 ± 899 vs. 2601 ± 5039, p=0.676), but significantly stronger than the ChAdOx1 vaccine (174 ± 96, p <0.0001). The neutralizing antibody titer generated by BNT162b2 was 6-fold higher than that generated by ChAdOx1, but lower than that by natural infection. T cell responses persisted for the 3 months in the BNT162b2 and natural infection but decreased in the ChAdOx1. CONCLUSIONS: Antibody responses after the 2 (nd) dose of BNT162b2 are higher than after the 2 (nd) dose of ChAdOx1 and like those occurring after natural infection. T cell responses are maintained longer in BNT162b2 vaccinees than in ChAdOx1 vaccinees.

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are expected to end the Coronavirus Diseases-19 (COVID- 19) pandemic. The lipid nanoparticleformulated mRNA-based vaccine, BNT162b2, developed by BioNTech/Pfizer has been reported to be 95% effective in preventing COVID-19 [1] . The ChAdOx1 nCoV-19 vaccine developed by Oxford University/AstraZeneca, which is a replication-deficient chimpanzee adenovirus vector-based vaccine, has been reported to be 70.4% effective [2] . Separate studies reported that BNT162b2 and ChaAdOx1 nCoV-19 elicited strong antibody responses and robust spike protein specific CD8 + and CD4 + T cell responses [3] [4] [5] [6] [7] [8] . In our previous study, antibody responses to BNT162b2 after the 1 st vaccination of a homogeneous population were faster and stronger than those to ChAdOx1 nCoV-19 but spike-specific T cell responses were similar [9] . However, there are limited comparisons of the detailed kinetic immunogenicity across different platformed, second doses completed ChAdOx1 and BNT162b2. Many studies have reported rapid waning of IgG antibodies within 3-4 months in patients naturally infected with COVID-19 [10] [11] [12] [13] , and our previous findings were consistent with those studies [14] . However, studies directly comparing immune responses to natural infection and vaccines have also been limited. In this study, we examined immune responses, both humoral and cellular, to the BNT162b2 and ChAdOx1 nCoV-19 vaccines over a 3month period and compared the antibody and T cell responses induced by the vaccines with those generated by natural COVID-19 infection.

A c c e p t e d M a n u s c r i p t

A nationwide vaccination program against COVID-19 is ongoing in South Korea. Our study enrolled HCWs who received the ChAdOx1 nCoV-19 vaccine (AZ) or the BNT162b2 vaccine (PF) at a tertiary care hospital in Seoul, South Korea, between March 5th and March 25th, 2021. In accord with the policy of the Korean government, the BNT162b2 vaccine was assigned to high-risk HCWs in direct contact with COVID-19 patients, and the ChAdOx1 vaccine was assigned to those involved in general patient care. All participants agreed to peripheral blood sampling, and blood sampling was carried out once before vaccination, for baseline serology. Thereafter, blood samples were taken from the participants vaccinated with NT162b2 at 3 weeks after the first dose, 2 weeks after the second dose (5 weeks after the first dose), and 12 weeks after the first dose. The blood samples collected from the participants vaccinated with the ChAdOx1 nCoV-19 vaccine were collected at 3, 8, and 12 weeks after the first dose, and 2 weeks after the second dose (14 after the first dose). COVID-19 naturally infected patients admitted to Asan Medical Center were enrolled between March 2020 and February 2021. COVID-19 infection was confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR) for the RdRp, N, and E genes of SARS-CoV-2 (Allplex TM 2019-nCoV assay, Seegene, Seoul, South Korea). All participants agreed to peripheral blood sampling, which was carried out on the day of hospital admission, and 1 month and 2 months, and either 3 or 4 months after symptom onset. The study was reviewed and approved by the Institutional Review Board of Asan Medical Center (IRB No. 2020-0297 and IRB No. 2021-0170). Informed consents were taken from all participants. M a n u s c r i p t

SARS-CoV-2 S1-specific IgG and IgM antibody titers were measured using an enzymelinked immunosorbent assay (ELISA) developed in-house, details of which are described in a previous report (8) . The data are presented as International Units per milliliter (IU/ml), which is standardized with reference pooled sera from International Vaccine Institute (Seoul, South Korea).To determine cut-off values for the ELISA, the mean and standard deviation (SD) of negative control plasma were measured, and cut-off values were defined as mean IU plus three-fold the SD value; the cut-off value was 10 IU/ml for IgG, as reported previously [15, 16] .

We also measured plasma levels of neutralizing antibodies using a microneutralization A c c e p t e d M a n u s c r i p t

Statistical analyses were performed with SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA), and graphs were plotted with GraphPad Prism 8. Depending on normality of the data, we used the Chi-squared test or Fisher's exact test to analyze categorical variables, and Student's t-test or the Mann-Whitney U test for continuous variables. All tests of significance were two-tailed, and P values < 0.05 were considered statistically significant.

A total of 129 HCWs were enrolled in this study; 93 (72%) were vaccinated with ChAdOx1, 36 (28%) with BNT162b2, and 8 of the ChAdOx1 vaccinees dropped out; thus 85 ChAdOx1 and 36 BNT162b2 vaccinees were finally analyzed. The baseline characteristics of the participants are shown in Table 1 . Median age was higher in the ChAdOx1 participants (36 vs. 32, P = 0.006; Table 1 ). After the second dose of vaccine, local and systemic reactogenicity as severity grade were significantly higher in the ChAdOx1 participants than the BNT162b2 participants (P = 0.037 and P < 0.001, respectively; Table 1 ).

Twenty-six patients with confirmed COVID-19 were classified according to disease severity:

1 as asymptomatic, 1 as mild, 8 as moderate, 12 as severe, and 4 as critical. Detailed baseline characteristics and clinical outcomes of the patients are shown in Table 2 .

A c c e p t e d M a n u s c r i p t S1-IgG antibody responses SARS-CoV-2 S1 protein-specific IgG antibody (S1-IgG) titers were measured in 36 of the plasma samples from the participants injected with the BNT162b2 vaccine at baseline, and at 5 and 12 weeks, and in 35 of the plasma samples at 3 weeks after the first vaccination. S1-IgG titers were significantly higher 2 weeks after the second dose (5 weeks after the first dose; mean ± SD, IU/ml, 2241 ± 899) than at 3 weeks after the first dose (351 ± 180, p < 0.0001). They then decreased by 12 weeks after the first dose (834 ± 467, p < 0.0001, Fig.   1A ). S1-IgG was measured in 84 plasma samples from ChAdOx1 nCoV-19 vaccinees at baseline, 85 at 3 and 8 weeks, 82 at 12 weeks, and 83 at 14 weeks after the first vaccination. S1-IgG titers declined between 3 and 12 weeks after the first vaccination (at 3 weeks, 142 ± 139; at 12 weeks, 42 ± 29; p < 0.0001, Fig. 1B ). At 2 weeks after the second dose (14 weeks after the first dose), S1-IgG was higher than at 12 weeks but not significantly different from at 3 weeks (at 14 weeks, 174 ± 96; between 12 and 14 weeks, p < 0.0001; between 3 and 14 weeks, p = 0.067, Fig. 1B ).

For the naturally infected patients, S1-IgG was measured in 21 plasma samples on admission (median, 6 days; range, 0-13 days after symptom onset), 24 samples at 4 weeks after symptom onset (median, 30 days; range, 15-44 days), 18 samples at 8 weeks after symptom onset (median, 54 days; range, 47-74 days), and 26 samples at 15 weeks after symptom onset (median, 105 days; range, 81-140 days). The highest S1-IgG titers were measured at 4 weeks (2601 ± 5039); they then declined to 15 weeks (457 ± 620, p = 0.022, Fig. 1C ).

At 4 weeks after symptom onset, the naturally infected patients had almost the same antibody levels as 2 nd dose BNT162b2 vaccinees at 5 weeks (2601 ± 5039 vs. 2241 ± 899, p = 0.676), but significantly higher than at 2 weeks after the 2 nd dose of ChAdOx1 nCoV-19

A c c e p t e d M a n u s c r i p t (174 ± 96at 14 weeks, p <0.0001). At 3 months after the 1 st vaccination or natural infection, S1-IgG antibody of ChAdOx1 nCoV-19 (174 ± 96at 14 weeks) was significantly lower than BNT162b2 (834 ± 467at 12 weeks, p < 0.0001) or natural infection (457 ± 620at 15 weeks, p = 0.0001, Fig. 1D ). Also, the neutralizing antibody titers were measured in the plasmas of 18 natural infected patients at 4 weeks after symptom onset (peak response). After the 1 st dose, the neutralizing antibody titer of the BNT161b2 vaccinees was about 1.6-fold higher than that of the ChAdOx1 nCoV-19 vaccinees (183.1 ± 155.6 vs. 116.6 ± 116.2, p = 0.036, Fig. 1E ). After the 2 nd dose, it was about 6-fold higher than that of the ChAdOx1 nCoV-19 vaccinees (2544 ± 2547 vs. 447 ± 341, p <0.0001), but lower than that of natural infected patients at 4 weeks (vs. 4708 ± 3270, p = 0.010). Neutralizing antibody titer was significantly correlated with S1-IgG antibody titer (Pearson r = 0.747, p < 0.0001; Supplementary Fig. 1 ). A c c e p t e d M a n u s c r i p t

In this study we assessed the immunogenicity of 2 nd dose-completed BNT162b2 and ChAdOx1 nCoV-19 vaccines and compared the antibody and T cell responses induced by the vaccines with those evoked by natural infection with COVID-19. After the 2 nd dose, S1-IgG antibody responses to BNT162b2 vaccine were similar to those of naturally infected patients and significantly higher than those to ChAdOx1 nCoV-19 vaccine. Neutralizing antibody after the 2 nd dose was also significantly higher in BNT162b2 vaccinees than in ChAdOx1 nCoV-19 vaccinees, but lower than in natural infection. S1-IgG antibody declined over 3 months in both BNT162b2 vaccinees and naturally infected patients. Three months after the 1 st dose, the S1-IgG antibody response to BNT162b2 was highest, and the response to ChAdOx1 was lower than to the other groups. With both vaccines, the 2 nd doses did not elicit significant IFN-γ-producing T cell responses. The T cell response to BNT162b2 was moreor-less maintained, but that to ChAdOx1 decreased by 3 months after the 1 st dose. The T cell responses to natural infection was constant for 3 months after the infection.

In our previous study, the 1 st dose of BNT162b2 elicited a higher antibody response than ChAdOx1 nCoV-19 [9] . The differences between the S1-IgG and neutralizing antibody responses to the two vaccines increased after the 2 nd dose (Fig. 1) . After the 2 nd dose, BNT162b2b elicited a similar S1-IgG antibody response to that in the naturally infected patients, but the response to ChAdOx1 was significantly lower. The spike glycoprotein of SARS-CoV-2 binds a receptor, angiotensin converting enzyme 2 (ACE2), through a domain that is part of S1, and mediates cell entry [17, 18] . The spike protein is a key target for virus neutralizing antibodies [19] and a prime candidate for vaccine development. The ChAdOx1 nCoV-19 vaccine contains the full-length spike protein along with the leader sequence of A c c e p t e d M a n u s c r i p t tissue plasminogen activator [20] . The BNT162b2 vaccine also encodes the full-length spike protein, which is stabilized in the prefusion conformation by mutations of residues 986 and 987 to prolines [21, 22] . This structural difference between the spike proteins may affect antibody production, and the difference between the adenovirus-vector-based platform and the mRNA-based platform may also partly explain the discrepancy in antibody response between the two vaccines.

To the best of our knowledge, there are very limited data directly comparing SARS-CoV-2specific T cell responses to the different COVID-19 vaccine platforms after the 1 st and 2 nd doses of vaccine. Our study revealed that the spike protein-specific IFN-γ-producing T cell response to the BNT162b2 vaccine was more stable over 3 months than that to the ChAdOx1 nCoV-19 vaccine. T cells may play a major role in the resolution of COVID-19 [23] , but the effects on long-term memory T cells and their effects on long-lasting immunity are unclear.

Nevertheless, current studies have shown that T cell responses remain robust up to 6 or 12 months after exposure to SARS-CoV-2 [24, 25] , even though they are accompanied by waning of antibody responses. Jung et al. also reported that SARS-CoV-2 spike, membrane, and nucleocapsid protein specific IFN-γ-producing T cell responses were sustained over 200 days after the infection [26] . Thus, vaccine-induced T cell responses may well contribute to long-term immunity. Although our findings indicate that the BNT162b2 vaccine elicits more durable SARS-CoV-2-specific T cell responses than the ChAdOx1 nCoV-19 vaccine, further studies are needed to assess which vaccine platform may be superior in terms of long-term immunity against SARS-CoV-2.

In both BNT162b2 vaccinees and natural-infected patients, S1-IgG antibody declined significantly at 3 months after vaccination / infection. Other studies have reported results consistent with ours, namely, waning of spike-IgG antibody to the BNT162b2 vaccine [27, 28] and to natural COVID-19 infections [11, 12, 24] . However, the previous study reported A c c e p t e d M a n u s c r i p t that antibody waning dynamics were various among natural-infected patients with rapid waning, slow waning, and persistent groups [29] . So, further detailed kinetic studies are needed on the different waning patterns of vaccine-induced immunity in terms of longevity.

In addition, S1-IgG antibody levels induced by the ChAdOx1 nCoV-19 vaccine declined between 3 weeks and 12 weeks after the 1 st dose, although we did not observe a further decline after the 2 nd dose. However, this waning immunity was reversed after the 2 nd dose of ChAdOx1 nCoV-19 vaccine, which was given in accordance with Korean national vaccine policy based on evidence that a 3-month interval between doses may be beneficial for protection against COVID-19 [30] . In contrast, even though the 2 nd dose was delayed, the ChAdOx1 vaccine induced a lower S1-IgG antibody titer at 3 months after the 1 st dose than The gradual reduction in antibody titers may affect the efficacy of the vaccines, especially to infections by variants. A current prime concern about COVID-19 is the emergence and spread of diverse variants of SARS-CoV-2. The B.1.617.2 (delta) variant, which is already dominant worldwide, has several spike protein mutations [32] that may affect immune responses to the key antigenic regions of this receptor-binding-protein [33] . Indeed, neutralizing antibody activity against the delta variant in BNT162b2 recipients is reported to be 5.8 times lower than that against wild-type SARS-CoV-2 [34] . Furthermore, the effectiveness of the mRNA vaccines in nursing home residents fell from 75% to 53% after 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the

vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK

Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates

Rapid and stable mobilization of CD8 + T cells by SARS-CoV-2 mRNA vaccine

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Rapid induction of antigen-specific CD4 + T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire

Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults

Persistence of IgG response to SARS-CoV-2

SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity

Detection of antibody to murine cytomegalovirus by enzyme-linked immunosorbent and indirect immunofluorescence assays

Calculation of the ELISA's cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

T cell responses in patients with COVID-19

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem celllike memory T cells

Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network

A c c e p t e d M a n u s c r i p t